Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension and Long-Term Observational Study of Atezolizumab
NCT03148418Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Sep 2017
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies
- Countries
- 32
01
Overview
Phase 3, open-label trial of atezolizumab in cancer (3 arms), sponsored by Roche. Primary endpoint: Number of Participants With Continued Access to Atezolizumab-Based Therapy and/or Comparator Agent(s) up to 10 years. Started Sep 2017; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
cancer
Beyond the preview
Go deeper on NCT03148418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03148418.